U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.09%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Piper Sandler Downgrades Humana (HUM) to Neutral
October 3, 2024 9:35 AM EDTPiper Sandler analyst Jessica Tassan downgraded Humana (NYSE: HUM) from Overweight to Neutral with a price target of $274.00 (from $392.00).
The analyst comments "HUM published an 8K indicating only 1.6M, or 25%, of the company's MA/ SNP members are enrolled in plans rated 4.0+ Stars for 2025.... More
Raymond James Reiterates Market Perform Rating on Humana (HUM)
October 3, 2024 6:17 AM EDTRaymond James analyst John Ransom reiterated a Market Perform rating and {REMOVEPT} price target on Humana (NYSE: HUM).
The analyst comments "HUM management hosted a call at noon today for the sell side, and the stock had a modest bounce from the initial sell-off, likely due to the not-zero chance that their appeal to CMS might succeed and that there are not zero offsets, including more TBC flexibility and the ability to migrate group MA members to a 4.5 Star plan. At the current price of $247/share (down ~$150 from the recent peak), we... More
Wells Fargo Reiterates Overweight Rating on Humana (HUM)
October 3, 2024 5:55 AM EDTWells Fargo analyst Stephen Baxter reiterated an Overweight rating and $387.00 price target on Humana (NYSE: HUM)
The analyst comments "Analysis of Plan Finder. Our review of Medicare Plan Finder suggested that contracts H5216, H5619, H6622, H0028, and H5525 were potentially at risk if filtering functionality was indicative of actual results. Of the... More
Bernstein SocGen Group Reiterates Market Perform Rating on Humana (HUM)
October 3, 2024 5:52 AM EDTBernstein SocGen Group analyst Lance Wilkes reiterated a Market Perform rating and $405.00 price target on Humana (NYSE: HUM)
The analyst comments "Yesterday HUM issued a press release outlining their MA offerings for 2025, which was marketing like in tone, presenting how attractive the plans are for... More
ConAgra (CAG) PT Lowered to $31 at Citi
October 3, 2024 5:41 AM EDTCiti analyst Thomas Palmer lowered the price target on ConAgra (NYSE: CAG) to $31.00 (from $33.00) while maintaining a Neutral rating.
The analyst comments "The CAG shares were down 8% today (the most among packaged food stocks by 500+bps) after reporting a sizable 1Q25 sales and... More
Stifel Reiterates Hold Rating on ConAgra (CAG)
October 3, 2024 5:29 AM EDTStifel analyst Matthew Smith reiterated a Hold rating and $30.00 price target on ConAgra (NYSE: CAG).
The analyst comments "Conagra reported a weaker-than-expected first quarter with sales, margin performance, and lower equity earnings relative to our estimates. EPS of $0.53 was down 20% and $0.06 below our estimate.... More
Goldman Sachs Reiterates Conviction Buy Rating on ConAgra (CAG)
October 3, 2024 5:21 AM EDTGoldman Sachs analyst Leah Jordan reiterated a Conviction Buy rating and $36.00 price target on ConAgra (NYSE: CAG).
The analyst comments "CAG traded down -8% (vs S&P 500 flat) after F1Q results and reiterated FY25 guidance. While the quarter came in softer-than-expected, in part due to a temporary manufacturing disruption with its Hebrew... More
